EARLY INTERVENTION FOR PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS

被引:4
作者
BRANSON, BM
机构
[1] Division of STD/HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA
关键词
D O I
10.1093/clinids/20.Supplement_1.S3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early intervention for persons infected with human immunodeficiency virus (HIV) involves characterization of the stage of HIV disease, institution of therapy to prevent associated infections and postpone deterioration of immune function, and assistance in preventing transmission of the virus. This review examines the available data on the efficacy of current recommendations regarding the evaluation and management of persons with early HIV infection. Existing evidence supports the efficacy of physical examination, monitoring of the CD4(+) cell count, tuberculin testing (with chemotherapy for persons who test positive), anergy testing, Papanicolaou testing and screening for gonorrhea and chlamydial infection (for high-risk women), screening for syphilis, antiretroviral therapy (for symptomatic patients), and guidance in reducing the transmission of HIV. Recommended measures for which evidence of clinical efficacy is less certain include immunization against infections due to influenza virus, Streptococcus pneumoniae, Haemophilus influenzae, and hepatitis B virus as well as antiretroviral therapy for asymptomatic persons. Quantitative measurement of viral titers appears promising for the monitoring of HIV disease and antiretroviral therapy; the correlations of these titers with clinical end points need to be confirmed.
引用
收藏
页码:S3 / S22
页数:20
相关论文
共 289 条
[51]   ZIDOVUDINE IN PERSONS WITH ASYMPTOMATIC HIV-INFECTION AND CD4+ CELL COUNTS GREATER-THAN 400 PER CUBIC MILLIMETER [J].
COOPER, DA ;
GATELL, JM ;
KROON, S ;
CLUMECK, N ;
MILLARD, J ;
GOEBEL, FD ;
BRUUN, JN ;
STINGL, G ;
MELVILLE, RL ;
GONZALEZLAHOZ, J ;
STEVENS, JW ;
FIDDIAN, AP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :297-303
[52]  
COOPER DA, 1985, LANCET, V1, P537
[53]   THE EFFICACY AND SAFETY OF ZIDOVUDINE WITH OR WITHOUT ACYCLOVIR IN THE TREATMENT OF PATIENTS WITH AIDS-RELATED COMPLEX [J].
COOPER, DA ;
PEDERSEN, C ;
AIUTI, F ;
VILDE, JL ;
RUHNKE, M ;
PEHRSON, PO ;
CLUMECK, N ;
FARTHING, C ;
LUTHY, R ;
DOHERTY, RR ;
CLOAD, PA .
AIDS, 1991, 5 (08) :933-943
[54]   SERUM BETA-2-MICROGLOBULIN AND C-REACTIVE PROTEIN CONCENTRATIONS IN VIRAL-INFECTIONS [J].
COOPER, EH ;
FORBES, MA ;
HAMBLING, MH .
JOURNAL OF CLINICAL PATHOLOGY, 1984, 37 (10) :1140-1143
[55]   SURVIVAL EXPERIENCE AMONG PATIENTS WITH AIDS RECEIVING ZIDOVUDINE - FOLLOW-UP OF PATIENTS IN A COMPASSIONATE PLEA PROGRAM [J].
CREAGHKIRK, T ;
DOI, P ;
ANDREWS, E ;
NUSINOFFLEHRMAN, S ;
TILSON, H ;
HOTH, D ;
BARRY, DW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (20) :3009-3015
[56]   TRANSIENT HIGH-LEVELS OF VIREMIA IN PATIENTS WITH PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
DAAR, ES ;
MOUDGIL, T ;
MEYER, RD ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (14) :961-964
[57]  
DECLERCQ E, 1991, J ACQ IMMUN DEF SYND, V4, P207
[58]   SERUM P24 ANTIGEN LEVEL AS AN INTERMEDIATE END-POINT IN CLINICAL-TRIALS OF ZIDOVUDINE IN PEOPLE INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
DEGRUTTOLA, V ;
BECKETT, LA ;
COOMBS, RW ;
ARDUINO, JM ;
BALFOUR, HH ;
RASHEED, S ;
HOLLINGER, FB ;
FISCHL, MA ;
VOLBERDING, P ;
GROUP, TACT .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (04) :713-721
[59]  
DETELS R, 1988, J ACQ IMMUN DEF SYND, V1, P390
[60]  
DEWOLF F, 1988, J INFECT DIS, V158, P615, DOI 10.1093/infdis/158.3.615